Smith & Nephew plc (SNN) Stock Score, Valuation & Financial Research
Smith & Nephew plc is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 47/100.
Quick answer for SNN
Smith & Nephew plc currently has a Wall Street Score of 47/100. The stored market price is $27.5. Its financial score is 30/100. Its valuation score is 33/100. These figures are a research snapshot, not a buy or sell recommendation.
What Smith & Nephew plc does
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enab
SNN financial snapshot
- Wall Street Score:
- 47/100
- Current price:
- $27.5
- Market capitalization:
- $11.55B
- Revenue:
- $11.99B
- Net income:
- $1.04B
- Free cash flow:
- $854.0M
- Cash:
- $557.0M
- Total debt:
- $3.33B
- EPS:
- 1.46
- P/E ratio:
- 18.8x
- Financial score:
- 30/100
- Valuation score:
- 33/100
- Revenue score:
- 46/100
What stands out
- Reported year-over-year revenue growth is +0.9%.
- Free cash flow is $854.0M, showing positive cash generation.
- The balance sheet shows $557.0M of cash versus $3.33B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 33/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 30/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research SNN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.